Status:
UNKNOWN
Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic
Lead Sponsor:
Baylor College of Medicine
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Acute stroke afflicts nearly 700,000 patients in the US and is the number 3 cause of death. Only 2-9% of this large number is treated with t-PA if they arrive within 4.5 hours. An equally small percen...
Detailed Description
In the past we used 30% lower dose of abciximab compared to the cardiac trials and the discontinued ABESTT stroke trial. There were no symptomatic intracranial hemorrhages or thromboyctopenia in our s...
Eligibility Criteria
Inclusion
- Subjects are 18 years or older
- Anterior Circulation stroke within the last six hours
- Posterior Circulation stroke within the last 12 hours
Exclusion
- Initial CT of the head suggests stroke like symptoms are not due to an ischemic stroke but a result of hemorrhage or tumor
- Platelet count below 100,000
- PTT greater than 75 while on treatment with heparin
- INR greater than 2.5 while on treatment with warfarin
- ACT\>250
- Have clinical signs and symptoms of liver failure or elevations in AST, and ALT \> 3 times the normal values.
- Creatinine greater than 2
- Treatment team considers the patient to be at increased risk of intra-cerebral hemorrhages or systemic bleeding
- Pre-morbid modified Rankin score \>2 suggesting a functionally dependent patient.
Key Trial Info
Start Date :
February 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05415150
Start Date
February 18 2022
End Date
May 31 2024
Last Update
June 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Michael E. DeBakey VA Medical Center
Houston, Texas, United States, 77030